7α-Methyl-19-nortestasterone (MENT): The optimal androgen for male contraception and replacement therapy

International Journal of Andrology, Supplement

Volumn 23, Issue 2, 2000, Pages 13-15

  Sundaram, Kalyan ^a   Kumar, Narender ^a  

^a POPULATION COUNCIL   (United States)

Author keywords

7 Methyl 19 nortestosterone; Androgen; Male contraceptive implants; Prostate

Indexed keywords

ANDROGEN; TESTOSTERONE; TRESTOLONE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; MALE CONTRACEPTIVE AGENT; NANDROLONE;

CONFERENCE PAPER; CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; MALE; PRIORITY JOURNAL; ARTICLE; BIOAVAILABILITY; DRUG IMPLANT;

BIOLOGICAL AVAILABILITY; CONTRACEPTIVE AGENTS, MALE; DRUG IMPLANTS; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; NANDROLONE;

EID: 0034114262     PISSN: 13504908     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (11)

1. Agarwal, A. K. & Monder, C. (1988) In vitro metabolism of 7α-methyl-19-nortestosterone by rat liver, prostate, and epididymis. Endocrinology, 123, 2187-2193.
2. Anderson, R. A., Martin, C. W., Kung, A. W. C., Everington, D., Pun, T. C., Tan, K. C. B., Bancroft, J., Sundaram, K., Moo-Young, A. J. & Baird, D. T. (1999) 7α-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. Journal of Clinical Endocrinology and Metabolism, 84, 3556-3562.
3. Behre, H. M., Oberpenning, F. & Nieschlag, E. (1990) Comparative pharmacokinetics of androgen preparations: application of computer analysis and simulation. In: Testosterone: Action, Deficiency, Substitution (eds E. Nieschlag & H. M. Behre), pp. 115-135. Springer-Verlag, Berlin.
4. Bruchovsky, N. & Wilson, J. D. (1968) The conversion of testosterone to 5α-androstan-17-ol-3-one by rat prostate in vivo and in vitro. Journal of Biological Chemistry, 243, 2012-2021.
5. Cummings, D. E., Kumar, N., Bardin, C. W., Sundaram, K. & Bremner, W. J. (1998) Prostate-sparing effects in primates of the potent androgen 7α-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. Journal of Clinical Endocrinology and Metabolism, 83, 4212-4219.
6. Handelsman, D. (1990) Pharmacology of testosterone pellet implants. In: Testosterone: Action Deficiency, Substitution (eds E. Nieschlag & H. M. Behre), pp. 136-154. Springer-Verlag, Berlin.
7. Kumar, N., Didolkar, A. K., Monder, C., Bardin, C. W. & Sundaram, K. (1992) The biological activity of 7α-methyl-19-nortestosterone is not amplified in male reproductive tract as is that of testosterone. Endocrinology, 130, 3677-3683.
8. Kumar, N., Suvisaari, J., Tsong, Y.-Y., Aguillaume, C., Bardin, C. W., Lähteenmäki, P. & Sundaram, K. (1997) Pharmacokinetics of 7α-methyl-19-nortestosterone in men and Cynomolgus monkeys. Journal of Andrology, 18, 352-358.
9. Noe, G., Suvisaari, J., Martin, C., Moo-Young, A. J., Sundaram, K., Saleh, S. I., Quintero, E., Croxatto, H. B. & Lähteenmäki, P. (1999) Gonadotrophin and testosterone suppression by 7α-methyl-19-nortestosterone acetate administered by subdermal implant to healthy men. Human Reproduction, 14, 2200-2206.
10. Partsch, C. J., Weinbauer, G. F., Fang, R. & Nieschlag, E. (1995) Injectable testosterone undecanoate has more favorable pharmacokinetics and pharmacodynamics than testosterone enanthale. European Journal of Endocrinology, 132, 514-519.
11. Sundaram, K., Keizer-Zucker, A., Thau, R. B. & Bardin, C. W. (1987) Reversal of testicular function after prolonged suppression with an LHRH agonist in Rhesus monkeys. Journal of Andrology, 8, 103-107.